ABSTRACT

The current research work is mainly focused to improve the solubility and dissolution rate of BCS Class II drug flurbiprofen with the application of liquisolid technology. Flurbiprofen is selected as the model drug as it belongs to BCS Class II, and has extremely low water solubility of 10.45 3.2 g/ml. It is a non-steroidal anti-inflammatory drug andused to treat of rheumatoid arthritis, osteoarthritis and spondylitis. The Flurbiprofen liquisolid compacts were prepared and subjected to evaluation. After screening various solvents, PEG 400 was chosen as non-volatile liquid vehicle as it showed maximum solubility for drug.Theliquid medication was prepared containing drug in vehicle of various concentration of 33.33%, 40% and 50%. This is further converted to dry powder by admixing with suitable carrier (Avicel PH 102) and coating agent (Cab-O-Sil M5). These powdered liquisolid formulations were subjected to pre-compression rheological studies to determine their flow property. They are further compressed to obtain various liquisolid compacts ranging from TF1 to TF9. They are further subjected to post-compression evaluation parameters such as weight variation, content uniformity, hardness, friability, disintegration and in vitro dissolution. The dissolution efficiency at 21 minutes (DE21) for optimized TF7 liquisolid compact was found to be 24.41 and that of directly compressed tablet was found to be 2.44 in pH 7.4 phosphate buffer solution. The most likely reason for improved solubility may be due to improved wettability and greater surface area of drug exposed to dissolution media. FTIR and DSC studies confirmed no drug- excipient incompatibility. SEM and PXRD studies revealed the transformation of crystalline to amorphous nature of drug. Finally, it can be concluded that enhanced solubility of drug which in turn enhanced dissolution profile Flurbiprofen was successfully achieved using liquisolid compact technique. Keywords: Liquisolid technique, Flurbiprofen, solubility enhancement, carrier material, coating material
Publication date: 01/10/2021

https://ijbpas.com/pdf/2021/October/MS_IJBPAS_2021_OCT_SPCL_1042.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2021/10.10.1042